基础医学与临床 ›› 2021, Vol. 41 ›› Issue (12): 1802-1806.

• 临床研究 • 上一篇    下一篇

甲磺酸阿帕替尼治疗转移性结直肠癌的临床观察

陈竹1, 刘艳1, 高丽花1, 陈不尤2, 唐爱华3, 刘军1*   

  1. 南通大学附属医院 1.肿瘤化疗科; 2.肿瘤放疗科; 3.儿内科,江苏 南通 226001
  • 收稿日期:2020-09-09 修回日期:2020-12-20 发布日期:2021-12-03
  • 通讯作者: *liujun11301@hotmail.com
  • 基金资助:
    南通市科技计划项目(MS12017017-6)

Clinical observation of apatinib in the treatment of metastatic colorectal cancer

CHEN Zhu1, LIU Yan1, GAO Li-hua1, CHEN Bu-you2, TANG Ai-hua3, LIU Jun1*   

  1. 1. Department of Chemotherapy; 2. Department of Radiotherapy; 3. Department of Pediatrics,the Affiliated Hospital of Nantong University, Nantong 226001, China
  • Received:2020-09-09 Revised:2020-12-20 Published:2021-12-03
  • Contact: *liujun11301@hotmail.com

摘要: 目的 评价含甲磺酸阿帕替尼方案治疗转移性结直肠癌(mCRC)的疗效和安全性。方法 回顾性分析65例含甲磺酸阿帕替尼方案治疗的mCRC患者临床资料,评估影响患者近期有效率、无进展生存时间(PFS)和不良反应等因素。结果 63例可评估疗效患者疾病控制率为69.9%。一线、二线和三线及以上治疗患者的中位PFS分别为9.3个月、5.8个月和3.3个月(P<0.001)。三线及以上治疗患者中阿帕替尼组和阿帕替尼联合化疗组PFS分别为2.9个月和3.3个月。肝转移患者治疗前后血清胆碱酯酶和白蛋白浓度无明显差异。不良反应主要为1~2级高血压、蛋白尿、骨髓抑制和手足综合征。结论 阿帕替尼是mCRC的有效治疗方案,对肝脏储备功能影响小,毒性可控。

关键词: 肠道肿瘤, 甲磺酸阿帕替尼, 临床疗效, 安全性

Abstract: Objective To evaluate the efficacy and safety of apatinib in the treatment of metastatic colorectal cancer (mCRC). Methods Sixty-five patients with mCRC treated with apatinib were enrolled in this study for retrospective analysis. The factors affecting the recent effective, progression-free survival (PFS) and adverse reactions were evaluated. Results The disease control rate in 63 evaluable patients was 69.9%. The median PFS for patients received first-line, second-line, and third-line and above apatinib treatment were 9.3 months, 5.8 months, and 3.3 months, respectively(P<0.001). The PFS in the apatinib group and the apatinib/chemotherapy combination group in the third-line and above treatment were 2.9 months and 3.3 months, respectively. There was no significant difference in serum cholinesterase and albumin concentrations between patients with liver metastasis before and after treatment. Adverse reactions were mainly grade 1 to 2 hypertension, proteinuria, myelosuppression and hand-foot syndrome. Conclusions Apatinib is an effective treatment with controllable toxicity for mCRC, which has mild adverse effect on liver reserve function.

Key words: intestinal neoplasms, apatinib, clinical efficacy, safety

中图分类号: